Status:
UNKNOWN
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Lead Sponsor:
Peking University People's Hospital
Conditions:
Donor Lymphocyte Infusion
Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
5-60 years
Phase:
PHASE2
Brief Summary
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse. Previous studies from investigators reported an associ...
Eligibility Criteria
Inclusion
- (1) acute leukemia in first complete or second complete remission;
- (2) relapse after an allotransplant;
- (3) had full or partial donor chimerism;
- (4) received re-induction chemotherapy and DLI and achieved a negative MRD-test.
Exclusion
- (1) active GvHD
- (2) active infection
- (3) organ dysfunction
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03297528
Start Date
March 1 2017
End Date
October 1 2021
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China, 100044